Table 4.

Patient-Reported Outcome Measures Characteristics and Study Population Characteristics

PROM (authors/country/year/language)	Construct	PROM characteristics							Population characteristics
		Mode of administration	No. of factors	No. of items	Recall period	Response option	Interpretation of scoring	Response rate	Sample size	Age (years; mean)	Gender (% female)	Ethnicity (% white/Caucasian)	Disease type	Treatment	Time since treatment (years)
Fatigue thermometer (Brand et al.; United States; 2016; English)57	Cancer-related fatigue	nr	n/a	1	7 days	10-point Likert scale and visual analogue scale	0 no fatigue, 1–3 mild, 4–6 moderate, 7–10 severe	178/191	142	12–32 (20.24)	53	90	Low-grade glioma, embryonal tumor, germ cell, craniopharyngioma, choroid plexus, and high-grade glioma.	nr	2–27 (mean 10.55)
Pain thermometer (Chordas et al.; United States; 2013, English)58	Pain	nr	n/a	1	7 days	10-point Likert scale and visual analogue scale	0–3 mild pain, 4–6 moderate pain, 7–10 severe pain	116/163	99	13–32 (19.95)	52	86.8	Low-grade glioma, embryonal tumor, ependymoma, germ cell, craniopharyngioma,	nr	At least 1 year
Perceived Barriers Scale (Strauser et al.; United States; 2019; English)59	Perceived barriers to career development and employment	nr	Two: external barriers, internal barriers	12	nr	11-point Likert scale (0 = not a barrier, midpoint “somewhat a barrier, 10 = ‘major barrier’)”	nr	nr	110	18–30 (23.05)	52.7	90	Central nervous system tumors	Surgery, surgery/radiotherapy/chemotherapy, surgery/radiation, surgery/chemotherapy, radiation, radiation/chemotherapy, chemotherapy, stem cell transplant	At least 2 years
PedsFACT-BrS (Yoo et al.; Korea; 2010; Korean)60	Quality of life	nr	Four; physical, emotional, social, and familial well-being; brain tumor specific	37	4 weeks	5-point Likert scale	nr	nr	161	13–18 (15.53)	41.61	nr	Medulloblastoma, gliom, germ cell tumor, peripheral neuroendocrine tumor	Surgery, surgery/chemotherapy/radiotherapy, surgery/radiotherapy	nr